Fed. Circ. Sides With Sanofi In Patent Spat With Novo
In the U.S. Court of Appeals for the Federal Circuit on Wednesday, circuit judges affirmed the U.S. District Court for the District of New Jersey's February ruling that Novo lacked a “reasonable likelihood” of winning the case.
The patent spat is over Sanofi's SoloStar product, a once-a-day insulin injection pen that Novo claims...
To view the full article, register now.